Repligen reaches Phase IIb with Uridine

Repligen launches clinical phase 2b for bipolar depressive syndromes on 150 patients. by Caroline A. Falciola, PhD , 07/11/2008

AEterna's share to rise by 32%

Following AEterna's annoucement of 2nd stage Phase II enrolment for endometrial cancer, the compagny's share closed with a 32% increase. by Caroline A. Falciola, PhD , 04/11/2008

Targeting MS at the root - vaccine developments

Currently approved MS treatments are not very efficient on the disease's relapses, but many new peptide-based vaccines are being clinically tested and show very promising results27/10/2008

On the look-out for new treatments of cancer therapies counter-effects

Biotec Pharmacon ASA launches phase III trials for their lead immuno-modulating compound in oral mucositis treatment.23/10/2008

Multiple Sclerosis And Therapeutic Monoclonal Antibodies

Monoclonal antibodies represent one of the most innovative and promising therapeutic approaches of the last two decades. 03/07/2008

Neural Stem Cells

In the USA, it is estimated that 1.5 million Americans have Parkinson's disease and 60,000 new cases are diagnosed each year. Moreover, 30,000 Americans suffer from Amyotrophic Lateral Sclerosis, with 5,600 new cases diagnosed each year. Finally, one out of every 10,000 Americans has Huntington's Disease. Concomitantly, these numbers underline why there is a huge potential for treatments. 23/08/2007